MedTrace Logo

ATOM_local Ablative Therapy

NCT01941654 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 18

Last updated 2020-06-18

No results posted yet for this study

Summary

To determine the efficacy of preemptive local ablative therapy in NSCLC patients with activating EGFR mutation who have oligometastatic residual metabolic-active disease after first-line EGFR TKI, as measured by PFS rate at 1 year from the trial enrollment.

Conditions

  • NSCLC
  • Activating EGFR Mutation

Interventions

RADIATION

preemptive local ablative therapy

DRUG

Oral TKI

Sponsors & Collaborators

  • Pamela Youde Nethersole Eastern Hospital

    collaborator OTHER

  • Chinese University of Hong Kong

    lead OTHER

Principal Investigators

  • Kwok Chi LAM, FRCP · Prince of Wales Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-09-18
Primary Completion
2017-12-31
Completion
2020-05-28

Countries

  • Hong Kong

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01941654 on ClinicalTrials.gov